Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like MACI Arthro and international expansion. The Q&A highlights positive sentiment from analysts, with no significant competitive threats and strong growth drivers. The company's expanded sales force and BARDA award further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, suggesting a stock price increase in the 2% to 8% range.
Key Financial Performance
Total Revenue $68.4 million, increased 30% year-over-year. Driven by substantial growth in both MACI and Burn Care businesses.
MACI Revenue $56.4 million, representing 22% growth year-over-year. Growth driven by double-digit volume growth, expanded sales force, and deeper penetration within surgeon practices.
Burn Care Revenue $12 million, increased over 90% year-over-year. Growth attributed to strong Epicel revenue of $10.9 million and NexoBrid revenue of $1.1 million, which increased nearly 60% versus the fourth quarter.
Gross Margin 72%, increased over 300 basis points year-over-year. Improvement driven by strong revenue performance.
Adjusted EBITDA Margin 14%, increased nearly 800 basis points year-over-year. Adjusted EBITDA grew 195% to $9.6 million, driven by revenue growth and operational efficiencies.
Free Cash Flow $15.1 million, representing the third consecutive quarter with free cash flow of $12 million or more. Growth attributed to the completion of the new manufacturing facility and strong cash generation.
Cash and Investments $211 million, an increase of nearly $50 million compared to the end of the first quarter last year. Growth driven by strong operating cash flow and free cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MACI Revenue Growth: MACI achieved record first-quarter revenue of $56 million, a 22% increase from the prior year. The trailing four-quarter revenue growth rate increased to 23%.
MACI Arthro: Progress in generating clinical data for MACI Arthro shows reduced postsurgical pain, improved range of motion, and faster recovery timelines. Early data has been accepted for publication.
FDA Approval for New Facility: FDA approved MACI commercial manufacturing at a new facility, increasing capacity for U.S. growth and enabling potential commercialization outside the U.S.
U.K. Market Expansion: Plans to submit a MACI marketing application in the U.K. later this year, with potential launch in 2027.
Revenue and Profit Growth: Total revenue increased by 30% to $68.4 million, with gross margin up 300 basis points to 72% and adjusted EBITDA margin up 800 basis points to 14%.
Burn Care Revenue: Burn Care revenue grew over 90% to $12 million, driven by strong Epicel and NexoBrid performance.
BARDA Award for NexoBrid: Received a BARDA award valued at up to $197 million for NexoBrid procurement and development, including $10 million for initial procurement over the next 12 months.
Sales Force Expansion: Expanded MACI sales force, leading to record biopsies, implants, and deeper penetration in surgeon practices.
Commercial Excellence Initiatives: Enhanced commercial analytics and standardized best practices to improve execution and penetration within the MACI surgeon user base.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company is working on submitting a MACI marketing application in the U.K. later this year, with potential commercialization in 2027. Regulatory approval processes can pose challenges and delays.
Strategic Execution Risks: The company is expanding its MACI sales force and implementing commercial excellence initiatives. Ensuring effective execution of these strategies is critical to achieving deeper market penetration and sustained growth.
Economic Uncertainties: The company’s financial performance is tied to broader economic conditions, which could impact revenue growth and cash flow generation.
Supply Chain and Manufacturing Risks: The company recently began commercial manufacturing at a new facility. Scaling up operations and ensuring consistent quality could pose challenges.
Market Conditions: The company’s growth is dependent on the adoption of its products like MACI and NexoBrid. Market acceptance and competition could impact performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year total revenue guidance range by $10 million, now expecting total revenue of $326 million to $336 million for 2026, representing approximately 20% growth at the midpoint.
MACI Revenue Guidance: Full-year MACI revenue guidance has been increased to $282 million to $288 million, up from the prior guidance of $280 million to $286 million. For the second quarter, MACI revenue is expected to be approximately $62.5 million to $63.5 million.
Burn Care Revenue Guidance: Full-year Burn Care revenue guidance has been increased to $44 million to $48 million, up from the prior guidance of $36 million to $40 million. Second-quarter Burn Care revenue is expected to be approximately $9 million to $10 million. Additionally, $5 million to $6 million of NexoBrid BARDA procurement revenue is expected in the second half of the year, starting in the third quarter.
Gross Margin and Adjusted EBITDA Margin: For the full year, gross margin is expected to be approximately 75%, and adjusted EBITDA margin is expected to be approximately 27%. For the second quarter, gross margin is expected to be approximately 72%, and adjusted EBITDA margin is expected to be approximately 18%.
NexoBrid BARDA Contract: The company announced a BARDA award valued at up to $197 million for the procurement and advanced development of NexoBrid. The base period contract of $35 million includes approximately $10 million over the next 12 months for initial procurement and development activities. Optional awards for additional procurement and development are included over a 10-year period.
MACI Manufacturing Expansion: The FDA approval for MACI commercial manufacturing at a new facility has been achieved, increasing manufacturing capacity to support long-term growth in the U.S. and enabling potential commercialization outside the U.S. A MACI marketing application is planned for submission in the U.K. later this year, with a potential launch in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key drivers for the updated guidance outlook, particularly for MACI trends and MACI Arthro in Q2?
A:The updated guidance reflects two key drivers: $4-5 million outperformance in Q1 and $5-6 million incremental NexoBrid BARDA revenue expected in H2. For Burn Care, $2 million of Q1 outperformance and $6 million BARDA revenue were included, leading to an 8% full-year growth. MACI saw a $2 million beat in Q1, contributing to a full-year guidance of $330 million at the midpoint, representing 20% company growth. Assumptions for MACI remain consistent, with high teens growth expected for Q2 and the back half of the year.
Q:How does the company view the competitive landscape with the potential entry of Agili-C?
A:The company views Agili-C as targeting older osteoarthritic patients as a bridge to knee replacement, with minimal overlap with MACI's younger, active patient population. Agili-C is contraindicated for patella defects, which is MACI's largest and fastest-growing segment. The company has not observed any significant impact from Agili-C and does not expect it to affect MACI's business.
Q:What progress has been made with MACI Arthro, and how is it contributing to growth?
A:MACI Arthro has shown strong progress, with over 1,000 surgeons trained, contributing to over half of implants. It has driven growth in smaller femoral condyle defects, with higher biopsy and implant growth rates among Arthro-trained surgeons. Leading indicators remain strong, and MACI Arthro is expected to continue contributing to growth.
Q:What is the status and expected impact of the BARDA award?
A:The BARDA award is a $200 million contract, with $35 million initially awarded. About two-thirds of the value flows to Vericel through procurement, VMI service revenue, and cost offsets. Initial procurement revenue of $5-6 million is expected in H2 2026, with the remainder in early 2027. Additional optional awards could increase procurement and support further development, including a blast trauma indication and room-temperature formulation.
Q:What is the company's view on potential ortho procedure volume pressures?
A:The company has not observed any slowdown in ortho procedure volumes and has not baked any such pressures into its guidance. Strong biopsy growth in Q4 and Q1, along with a robust pool of biopsies, positions the company well for continued growth.
Q:What is the international expansion opportunity for MACI?
A:The company plans to launch MACI in the U.K. in 2027, leveraging high surgeon awareness and advocacy. There is significant interest in Europe, where options for restorative cartilage repair are limited. The U.K. serves as a beachhead for broader international expansion.
Q:How is the expanded sales force contributing to growth?
A:The expanded sales force has contributed to strong Q1 performance, with higher growth rates in new and legacy territories. Biopsy growth per surgeon has accelerated, particularly in new territories, and the pull-through to implants has been strong. The new sales force is off to a strong start, with some territories already beyond breakeven.
Q:What drove the strong performance in the Burn Care segment, particularly for Epicel?
A:Epicel's strong performance was driven by biopsy growth and higher conversion rates of biopsies to grafts. The company has improved execution in evaluating and treating biopsies, leading to better patient outcomes. NexoBrid also showed progress, with a broadening number of ordering centers and increased utilization.
Q:What is the company's strategy for MACI Arthro clinical data and its impact on adoption?
A:The company is focused on building clinical data for MACI Arthro through case series and the MACI clinical outcomes registry. Early data shows positive outcomes, which could support broader adoption and insurance coverage over time. Clinical data is expected to reinforce MACI Arthro's value proposition.
Q:What is the segmentation of the cartilage repair market, and how does MACI fit in?
A:MACI remains the market leader in cartilage repair, targeting younger, active patients with clean cartilage injuries. The market includes older osteoarthritic patients for products like Agili-C and smaller defects for microfracture augmentation products. MACI's largest segment is patella defects, with strong growth in smaller femoral condyle defects driven by MACI Arthro.
Q:Review of Unclear Management Responses
A:Management did not provide specific metrics on the percentage of repeat versus first-time biopsy and implant surgeons or the exact incremental gains from the new sales force. Additionally, while they discussed the potential for a one-step MACI procedure, they did not provide concrete plans or timelines for its development.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arthro case
Arthro procedure
Arthro treatment
BARDA award
Burns Investor
Care margin
FDA approval
Factors result
Form today
Instructions Today
MACI Arthro
MACI commercialization
MACI marketing
MACI penetration
Mara discussion
NexoBrid BARDA
NexoBrid funding
NexoBrid market
NexoBrid period
NexoBrid procurement
Nick result
SEC discussion
SEC presentation
UK MACI
Vericel
award procurement
basis point
biopsy conversion
contract
development NexoBrid
digit biopsy
margin basis
measure
outcome MACI
penetration MACI
procurement development
record MACI
surgeon penetration
surgeon practice
VCEL Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like MACI Arthro and international expansion. The Q&A highlights positive sentiment from analysts, with no significant competitive threats and strong growth drivers. The company's expanded sales force and BARDA award further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, suggesting a stock price increase in the 2% to 8% range.
Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reflects strong financial performance with record-high gross and EBITDA margins, significant revenue growth, and a robust cash position. The Q&A highlights positive sentiment towards pricing strategies and surgeon adoption, though some guidance lacks specifics. Despite slightly lower MACI growth guidance for 2026, the overall outlook remains optimistic with ongoing expansion efforts and potential BARDA RFP opportunities. The positive financial metrics and strategic growth initiatives suggest a likely stock price increase in the short term.
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
VCEL Slides
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise2026-05-07
Vericel Q4 2025 slides: record margins offset by 2026 guidance2026-02-26
Vericel Q2 2025 slides: MACI drives 21% revenue growth, margins expand2025-07-31
Vericel Q1 2025 slides: record revenue offset by widening losses, raises guidance2025-05-08
VCEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
